Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aim: To examine the efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared with other antihyperglycaemic agents (AHAs) in large and unselected populations of the Lombardy and Apulia regions in Italy. Materials and Methods: An observational cohort study of first‐time users of GLP‐1RAs, SGLT2 inhibitors or other AHAs was conducted from 2010 to 2018. Death and cardiovascular (CV) events were evaluated using conditional Cox models in propensity‐score‐matched populations. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated for each region and in a meta‐analysis for pooled risks. Results: After propensity‐score matching, the Lombardy cohort included 18 716 and 11 683 patients and the Apulia cohort 9772 and 6046 patients for the GLP‐1RA and SGLT2 inhibitor groups, respectively. Use of GLP‐1RAs was associated with lower rates of death (HR 0.61, CI 0.56‐0.65, Lombardy; HR 0.63, CI 0.55‐0.71, Apulia), cerebrovascular disease and ischaemic stroke (HR 0.70, CI 0.63‐0.79; HR 0.72, CI 0.60‐0.87, Lombardy), peripheral vascular disease (HR 0.72, CI 0.64‐0.82, Lombardy; HR 0.80, CI 0.67‐0.98, Apulia), and lower limb complications (HR 0.67, CI 0.56‐0.81, Lombardy; HR 0.69, CI 0.51‐0.93, Apulia). Compared with other AHAs, SGLT2 inhibitor use decreased the risk of death (HR 0.47, CI 0.40‐0.54, Lombardy; HR 0.43, CI 0.32‐0.57, Apulia), cerebrovascular disease (HR 0.75, CI 0.61‐0.91, Lombardy; HR 0.72, CI 0.54‐0.96, Apulia), and heart failure (HR 0.56, CI 0.46‐0.70, Lombardy; HR 0.57, CI 0.42‐0.77, Apulia). In the pooled cohorts, a reduction in heart failure was also observed with GLP‐1RAs (HR 0.89, 95% CI 0.82‐0.97). Serious adverse events were quite low in frequency. Conclusion: Our findings from real‐world practice confirm the favourable effect of GLP‐1RAs and SGLT2 inhibitors on death and CV outcomes across both regions consistently. Thus, these drug classes should be preferentially considered in a broad type 2 diabetes population beyond those with CV disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2005) · Diabetes Care · doi:10.2337/diacare.28.suppl_1.s37 · Cited by 830
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Cited by
Myasoedova, V. A., Parisi, V., Moschetta, D., Valerio, V., Conte, M., Massaiu, I., Bozzi, M., Celeste, F., Leosco, D., Iaccarino, G., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01738-2 · Cited by 93
Self-citationCaruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
“The meta-analysis of five studies addressing the risk of heart failure-related outcomes as a secondary endpoint [17,19,21,22,25] showed an overall 12% reduction in initiators of GLP1RA vs.”
BackgroundMethodResultInfluentialSelf-citationLe, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“…separated Italian cohorts found that GLP-1 RA use decreased rates of PAD (Lombardy cohort: HR 0.72, 95% CI [0.64–0.82]; Apulia cohort: HR 0.80, 95% CI 0.67–0.98) and lower limb complications (Lombardy cohort: HR 0.67, 95% CI [0.56–0.81]; Apulia cohort: HR 0.69, 95% CI [0.51–0.93]) [75].”
BackgroundInfluentialYang, Y.-S., Chen, H.-H., Huang, C.-N., Hsu, C. Y., Hu, K.-C., & Kao, C.-H. (2022) · Diabetes Care · doi:10.2337/dc21-1993 · Cited by 35
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
Metadata
- Authors
- Baviera, M., Genovese, S., Lepore, V., Colacioppo, P., Robusto, F., Tettamanti, M., D'Ettorre, A., Avanzini, F., Fortino, I., Nicolucci, A., Roncaglioni, M. C., & Giorgino, F.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2021-03-15
- Volume
- 23
- Issue
- 7
- Pages
- 1484-1495
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3130013319
- Cited by
- 42
- References
- 13
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts. https://app.cochat.ai/papers/10.1111/dom.14361
- The paper
- Baviera, M., Genovese, S., Lepore, V., Colacioppo, P., Robusto, F., Tettamanti, M., D'Ettorre, A., Avanzini, F., Fortino, I., Nicolucci, A., Roncaglioni, M. C., & Giorgino, F. (2021). Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14361
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.